

# Synta66

Catalog No: tcsc0034949



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg



## Specifications

**CAS No:**

835904-51-3

**Formula:**

$C_{20}H_{17}FN_2O_3$

**Pathway:**

Membrane Transporter/Ion Channel

**Target:**

CRAC Channel

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 77.5 mg/mL (219.95 mM; Need ultrasonic); H<sub>2</sub>O :

**Observed Molecular Weight:**


352.36

## Product Description

Synta66 is an inhibitor of store-operated calcium entry channel **Orai**, which forms the pore of the **CRAC** channel, and used for the research of neurological disease.

IC50 & Target: Orai<sup>[1]</sup>

***In Vitro:*** Synta66 is an inhibitor of Orai, which forms the pore of the CRAC channel. Synta66 (10  $\mu$ M) attenuates peak SOCE in Müller glia. Synta66 (10  $\mu$ M) prevents orai channels mediating the residual SOC current in Trpc1<sup>-/-</sup> Müller cells<sup>[1]</sup>. Synta66 (10  $\mu$ M) nearly completely blocks the Ca<sup>2+</sup> entry signal evoked by CaCl<sub>2</sub> addition, whereas it moderately reduces Ca<sup>2+</sup> mobilization from stores with 10% to 30% in platelet. Synta66 (10  $\mu$ M) suppresses human platelet activation in plasma and whole-blood thrombus formation. Synta66 (10  $\mu$ M) also inhibits murine platelet responses and thrombus formation<sup>[2]</sup>. Synta66 (10  $\mu$ M) inhibits LAD2 human mast cell line. Synta66 (10  $\mu$ M) significantly inhibits Fc $\epsilon$ RI stimulated histamine and TNF $\alpha$  secretion, and has differential effects on Fc $\epsilon$ RI stimulated prostaglandin D2 and cytokine release in human lung mast cells (HLMCs)<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!